BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 23316013)

  • 21. Role of assessment for retreatment with Transarterial chemoembolization score in decision of Retreatment with trans-arterial chemo-embolization Sessions in patients with hepatocellular carcinoma.
    Abbasi AH; Abid S; Haq TU; Awan S
    J Ayub Med Coll Abbottabad; 2017; 29(3):378-383. PubMed ID: 29076665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact.
    Utsunomiya T; Shimada M; Kudo M; Ichida T; Matsui O; Izumi N; Matsuyama Y; Sakamoto M; Nakashima O; Ku Y; Kokudo N; Makuuchi M;
    Ann Surg; 2014 Feb; 259(2):336-45. PubMed ID: 23673768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
    Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation and reappraisal of the assessment for retreatment with transarterial chemoembolization score for unresectable non-metastatic hepatocellular carcinoma in a hepatitis b virus-endemic region.
    Ha Y; Lee JB; Shim JH; Kim KM; Lim YS; Yoon HK; Shin YM; Lee HC
    Eur Radiol; 2016 Oct; 26(10):3510-8. PubMed ID: 26747261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization.
    Hsu CY; Huang YH; Su CW; Lin HC; Chiang JH; Lee PC; Lee FY; Huo TI; Lee SD
    Liver Int; 2010 Jan; 30(1):77-84. PubMed ID: 19818004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion.
    Kim KM; Kim JH; Park IS; Ko GY; Yoon HK; Sung KB; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Gastroenterol Hepatol; 2009 May; 24(5):806-14. PubMed ID: 19207681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma.
    Pinato DJ; Sharma R
    Transl Res; 2012 Aug; 160(2):146-52. PubMed ID: 22677364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
    J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function.
    Hsu KF; Chu CH; Chan DC; Yu JC; Shih ML; Hsieh HF; Hsieh TY; Yu CY; Hsieh CB
    Eur J Radiol; 2012 Mar; 81(3):466-71. PubMed ID: 21376495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nomograms for Predicting Outcomes after Chemoembolization in Patients with Nonmetastatic Hepatocellular Carcinoma.
    Ha Y; Han S; Shim JH; Ko GY; Yoon HK; Sung KB; Lee D; Kim KM; Lim YS; Chung YH; Lee YS; Lee HC
    J Vasc Interv Radiol; 2015 Aug; 26(8):1093-1101.e1. PubMed ID: 26077020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard.
    Massarweh NN; Davila JA; El-Serag HB; Duan Z; Temple S; May S; Sada YH; Anaya DA
    J Surg Res; 2016 Feb; 200(2):552-9. PubMed ID: 26507276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum gamma-glutamyl-transferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma: external validation.
    Guiu B; Deschamps F; Boulin M; Boige V; Malka D; Ducreux M; Hillon P; de Baère T
    Cardiovasc Intervent Radiol; 2012 Oct; 35(5):1102-8. PubMed ID: 22009578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: influence of emergent versus elective procedures on patient survival and tumor recurrence rate.
    Stockland AH; Walser EM; Paz-Fumagalli R; McKinney JM; May GR
    Cardiovasc Intervent Radiol; 2007; 30(5):888-93. PubMed ID: 17619218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis.
    Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Pai JT; Loong CC; Chiou YY; Lee RC; Lee FY; Huo TI; Lee SD
    Ann Surg Oncol; 2012 Mar; 19(3):842-9. PubMed ID: 21913008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatocellular carcinoma: high hepatitis B viral load and mortality in patients treated with transarterial chemoembolization.
    Yu SJ; Lee JH; Jang ES; Cho EJ; Kwak MS; Yoon JH; Lee HS; Kim CY; Kim YJ
    Radiology; 2013 May; 267(2):638-47. PubMed ID: 23440326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival.
    Grieco A; Marcoccia S; Miele L; Marmiroli L; Caminiti G; Ragazzoni E; Cotroneo AR; Cefaro GA; Rapaccini GL; Gasbarrini G
    Hepatogastroenterology; 2003; 50(49):207-12. PubMed ID: 12630024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis.
    Hsu CY; Huang YH; Chiou YY; Su CW; Lin HC; Lee RC; Chiang JH; Huo TI; Lee FY; Lee SD
    Liver Transpl; 2011 May; 17(5):556-66. PubMed ID: 21506244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma.
    Brown DB; Fundakowski CE; Lisker-Melman M; Crippin JS; Pilgram TK; Chapman W; Darcy MD
    J Vasc Interv Radiol; 2004 Nov; 15(11):1209-18. PubMed ID: 15525739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Target lesion response predicts survival of patients with hepatocellular carcinoma retreated with transarterial chemoembolization.
    Zhang YF; Guo RP; OuYang HY; Shen JX; Zhao J; Tan GS; Le Y; Wei W; Shi M
    Liver Int; 2016 Oct; 36(10):1516-24. PubMed ID: 27105296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.
    Hu HT; Kim JH; Lee LS; Kim KA; Ko GY; Yoon HK; Sung KB; Gwon DI; Shin JH; Song HY
    J Vasc Interv Radiol; 2011 Jul; 22(7):917-23. PubMed ID: 21571545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.